Biotech | November 17, 2021
World’s first Donepezil patch to treat Alzheimer approved in South Korea
Launching in 2022, its availability will be expanded to the global market
Launching in 2022, its availability will be expanded to the global market
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The new facility will provide an important boost to vaccine capacity in Africa
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Subscribe To Our Newsletter & Stay Updated
